Corcept Therapeutics Has Q4 Prelims, 2021 Revenue Guidance

 Financial Highlights, 2021 Revenue Guidance and Legal Update

• Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019
• Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 2019
• 2021 revenue guidance $375 - 405 million
• Preliminary 2020 fully diluted GAAP net income $0.85 per share, compared to $0.77 per share in 2019
• Preliminary fourth quarter fully diluted GAAP net income $0.20 per share, compared to $0.24 per share in fourth quarter 2019
• Preliminary cash and investments at December 31, 2020 of $476.9 million, an increase
  of $161.6 million from December 31, 2019
• Patent Trial and Appeals Board affirms validity of all claims in Corcept’s U.S. Patent No.10,195,214 (patent term: 2037)

http://www.globenewswire.com/news-release/2021/02/08/2171704/0/en/Corcept-Therapeutics-Announces-Fourth-Quarter-Full-Year-2020-Preliminary-Selected-Financial-Results-and-2021-Revenue-Guidance-Provides-Corporate-Update.html